^
    Back
    Association details:
    Biomarker:NR2F1 overexpression
    Cancer:Melanoma
    Drug Class:MEK inhibitor +
    CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 2986: NR2F1 underlies persistence of residual disease in melanoma

    Published date:
    05/15/2020
    Excerpt:
    ...melanoma cells overexpressing NR2F1 were less sensitive to (CDK4/6i+MEKi) or BRAF and MEK inhibitors (BRAFi+MEKi) treatment in vitro and in vivo models, inhibiting apoptosis. Surprisingly, we did not find any evidence of decreased cell growth in our model.
    DOI:
    10.1158/1538-7445.AM2020-2986